Cancer Biomarkers: Clinical Aspects and Laboratory Determination
- 1st Edition - June 7, 2022
- Imprint: Elsevier
- Editors: Lakshmi V. Ramanathan, Martin Fleisher, Michael J. Duffy
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 2 4 3 0 2 - 2
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 2 4 3 0 3 - 9
Cancer Biomarkers: Clinical Aspects and Laboratory Determination provides a comprehensive overview of current biomarkers for cancer detection, monitoring and recurrence, focusing… Read more
Purchase options
Cancer Biomarkers: Clinical Aspects and Laboratory Determination provides a comprehensive overview of current biomarkers for cancer detection, monitoring and recurrence, focusing on emerging technologies, impacts on the field, and selected biomarkers currently used in clinical practice. The content highlights current laboratory tests used in the management of adult and pediatric cancer patients. In addition, it investigates the role of Circulating Tumor Cells and circulating tumor DNA as biomarkers in cancer management as well as cytokines in monitoring response to CAR T therapies.
This title is a perfect reference for clinical pathologists, laboratory scientists, medical technologists, physicians specializing in oncology, internal medicine, family practice and transplant medicine, resident physicians, medical students, nurse practitioners and clinical chemists.
- Provides insights into the overall complexity that the cancer patient presents and how laboratory tests are used in the management of care
- Discusses current and new technologies applicable to cancer biomarker evaluation, including the use of non-traditional specimens like saliva, fluids and uterine lavage
- Reviews current trends in liquid biopsy and cancer biomarkers
- Provides a roadmap for bringing new technologies and markers from the bench to the bedside in the quest for finding the ideal tumor marker
Clinical pathologists; laboratory scientists; medical technologists; physicians specializing in oncology, internal medicine, family practice and transplant medicine; resident physicians; medical students; nurse practitioners, clinical chemists
1. Overview of tumor markers, traditional and non-traditional (include glycans)
Ramanathan (US) & Meng (US) & Patel (US)
2. Laboratory testing in pediatric cancer patients
Patel (US)
3. The adult cancer patient: overview and current laboratory testing
McCash (US) and Pessin (UK)
4. Thyroglobulin measurement: its importance in monitoring and recurrence of thyroid cancer
Hoofnagle (Ireland) and Shuford (UK)
5. PSA, long term prognosis
Lilja (Spain)
6. Monoclonal gammopathy detection and current technologies
Karma (Canada)
7. Liquid biopsy potential and challenges
Danila (UK)
8. CAR T therapies and the management of toxicity
Banner (US)
9. Validating circulating tumor cells and cell free DNA as an LDT for use in the clinic
Fleisher (US) & Pentsova (Italy)
10. Saliva as a matrix for measurement of biomarkers
Punyadeera (India)
11. Emerging technologies in the detection and monitoring of cancer
Heller (US)
12. Oncometabolites
Patel (US) & Kukreja (Ireland)
13. Circulating cancer biomarkers: current status and future prospects
Duffy (Ireland)
Ramanathan (US) & Meng (US) & Patel (US)
2. Laboratory testing in pediatric cancer patients
Patel (US)
3. The adult cancer patient: overview and current laboratory testing
McCash (US) and Pessin (UK)
4. Thyroglobulin measurement: its importance in monitoring and recurrence of thyroid cancer
Hoofnagle (Ireland) and Shuford (UK)
5. PSA, long term prognosis
Lilja (Spain)
6. Monoclonal gammopathy detection and current technologies
Karma (Canada)
7. Liquid biopsy potential and challenges
Danila (UK)
8. CAR T therapies and the management of toxicity
Banner (US)
9. Validating circulating tumor cells and cell free DNA as an LDT for use in the clinic
Fleisher (US) & Pentsova (Italy)
10. Saliva as a matrix for measurement of biomarkers
Punyadeera (India)
11. Emerging technologies in the detection and monitoring of cancer
Heller (US)
12. Oncometabolites
Patel (US) & Kukreja (Ireland)
13. Circulating cancer biomarkers: current status and future prospects
Duffy (Ireland)
- Edition: 1
- Published: June 7, 2022
- Imprint: Elsevier
- Language: English
LR
Lakshmi V. Ramanathan
Dr. Lakshmi V. Ramanathan is the Service Chief of Clinical Chemistry in the Department of Laboratory Medicine at Memorial Sloan Kettering Cancer Center in New York City. Prior to joining Memorial Sloan Kettering Cancer Center, Dr. Ramanathan was the Director of Chemistry at Mount Sinai Medical Center in New York City. She is a licensed laboratory Director in the State of New York. Dr. Ramanathan obtained her PhD in Nutritional Biochemistry and Metabolism at Massachusetts Institute of Technology in Cambridge, Massachusetts, USA. Her interests include laboratory automation and biomarkers in cancer diagnostics as well as teaching Clinical Pathology and Laboratory Medicine to residents and fellows. She is very active in the American Association of Clinical Chemistry, is the founding Chair of the Tumor Markers Cancer Diagnostics Division and was the past chair of the New York metro section.
Affiliations and expertise
Service Chief of Clinical Chemistry in the Department of Laboratory Medicine at Memorial Sloan Kettering Cancer Center in New York City, USAMF
Martin Fleisher
Dr. Martin Fleisher is currently Emeritus in the Department of Laboratory Medicine at the Memorial Sloan-Kettering Cancer Center. During his tenure at MSKCC he served as Chief and Director of the Clinical Chemistry Laboratory and Chair of the Department of Clinical Laboratories. Dr. Fleisher is a licensed Laboratory Director in the States of New York.
Dr. Fleisher received his B.A. degree from Harper College, State University of New York (now Binghamton University). He was awarded a Masters and Doctorate degrees in Biochemistry, with honors, from New York University. As a graduate fellow at the New York University School of Medicine in the Departments of Biochemistry and Physiology, his doctoral research focused on protein chemistry and specifically enzymology. He is considered an expert in biomarker assay development and validation. Dr. Fleisher has over 200 publications, including five chapters, on his research, and has edited a book on the Clinical Biochemistry of Cancer. He holds five US patents.
Affiliations and expertise
Emeritus, Department of Laboratory Medicine, Memorial Sloan-Kettering Cancer CenterMD
Michael J. Duffy
Professor Duffy who is based at St Vincent’s University Hospital, Dublin and University College Dublin, has an international reputation for his research in cancer biomarkers. He has published over 250 papers on this topic, including articles in high impact journals such as Lancet, BMJ, J Natl Cancer Instit, Cancer Res, Clin Cancer Res, Ann Oncol and Clin Chem.
Professor Duffy received his BSc (Hons) from the National University of Ireland at Galway (Ireland) and his PhD from the University of Manchester (UK). In 2012, Professor Duffy was the recipient of the 2012 Abbott Award of the International Society of Oncology and BioMarkers (ISOBM). Other awards received by Professor Duffy include the St Luke’s Medal Lecture, the Conway Review Medal Lecture and the Lifetime Achievement Award of the Royal Academy of Medicine in Ireland and the National Committee for Biochemistry Award Medal Lecture of the Royal Irish Academy.
Affiliations and expertise
St Vincent’s University Hospital, Dublin and University College Dublin, IrelandRead Cancer Biomarkers: Clinical Aspects and Laboratory Determination on ScienceDirect